[Sponsored] Health care professionals can refer patients to the best options for diagnostic imaging covered by Medicare to give more people the medical assistance they need without extra financial stress. The post The Best Options for Diagnostic Imaging Covered by Medicare appeared first on MedCity News.
A prime example of elderspeak: Cindy Smith was visiting her father in his assisted living apartment in Roseville, California. An aide who was trying to induce him to do something — Smith no longer remembers exactly what — said, “Let me help you, sweetheart.” “He just gave her The Look — under his bushy eyebrows…
When President Donald Trump posted a satirical music video on social media in early October depicting his budget director, Russell Vought, as the Grim Reaper lording over Democrats in Congress, public health workers recognized a kernel of truth. Vought has exerted extraordinary control over government spending this year, usurping congressional decisions on how the nation’s…
Lisa Farris worried that a nasty infection from recent liposuction and a tummy tuck was rapidly getting worse. So she phoned the cosmetic surgery center to ask if she should head to the emergency room, she alleges in a lawsuit. The nurse who took the call at the Sono Bello center in Addison, Texas, told…
BioMarin Pharmaceutical’s acquisition of Amicus Therapeutics is a marriage of two rare disease biotech companies. Amicus’s two commercialized products, for the enzyme deficiencies Fabry disease and Pompe disease, are each projected to become blockbuster sellers. The post BioMarin’s Presence in Rare Enzyme Disorders Grows With $4.8B Amicus Therapeutics Acquisition appeared first on MedCity News.
As hospitals face ongoing cost pressures and supply chain disruptions, Allina Health is redesigning its procurement strategy by moving away from a decentralized sourcing model and toward an approach that prioritizes governance and tech-driven efficiencies. Chief Supply Chain Officer Tom Lubotsky shared how the health system is saving money and boosting supply chain resilience. The…
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent’s lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck’s blockbuster med Keytruda in a pivotal head-to-head study. The post Going In…
Many experts – be they venture capitalists or private equity investprs – shared their advice to biotech entrepreneurs navigating a tough funding envornment. The post How Can Startups Navigate the Difficult Funding Environment appeared first on MedCity News.
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals. The post Novo Nordisk Commits $285M to Ascendis to Kick Off Alliance on Longer-Acting GLP-1 Drugs appeared first…
Bain Capital’s buyout of Mitsubishi Tanabe Pharma brings a company with a drug portfolio and pipeline in areas such as immunology, central nervous system disorders, and metabolic disease. This business is the pharmaceuticals division of Japanese conglomerate Mitsubishi Chemical Group. The post Bain Capital Broadens Its Biotech Reach With $3.3B Deal for Mitsubishi Tanabe Pharma…